A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Key Inclusion Criteria:

1. CAR T cell naïve and eligible to receive a CD19 CART-cell therapy

2. Histologically confirmed large B-cell lymphoma, including the following typesdefined by (WHO 2022) or International Consensus Classification (2022)

• Diffuse large B-cell lymphoma (DLBCL)

• Transformations of indolent B-cell lymphomas (excluding Richter'stransformation)

• DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements

• High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)

• Primary mediastinal large B-cell lymphoma (PMBCL)

• Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)

3. Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containingfirst-line chemoimmunotherapy

4. Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesionduring Screening per Lugano Criteria

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

6. Adequate hematological, renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria:

1. Patients ineligible to receive CD19 CAR T-cell therapy

2. Primary CNS lymphoma

3. Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma,Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chroniclymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)

4. Patients with prior history of malignancy, other than aggressive relapsed orrefractory LBCL, unless the patient has been free of the disease for ≥ 2 years

5. Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment

6. Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply